stockportfolio.pro
Stocks / ARQT vs WRBY
ARQT vs WRBY
Arcutis Biotherapeutics, Inc. and Warby Parker Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arcutis Biotherapeutics, Inc. (ARQT) | Warby Parker Inc. (WRBY) | |
|---|---|---|
| Market cap | $3.0B | $3.2B |
| Revenue (latest FY) | $376.07M | $871.90M |
| Net income (latest FY) | $-16.14M | $1.64M |
| Revenue growth (5y CAGR) | — | 17.2% |
| Net margin | -4.3% | 0.2% |
| Return on equity | -8.5% | 0.4% |
| P/E ratio | — | 2581.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARQT — free Open WRBY — freeFrequently asked questions
Which is bigger, ARQT or WRBY?
Warby Parker Inc. is larger by market capitalization — $3.2B versus $3.0B.
Which grows faster, ARQT or WRBY?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.